Enlivex Therapeutics (NASDAQ:ENLV) Given New $80.00 Price Target at HC Wainwright

by · The Markets Daily

Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) had its target price boosted by equities researchers at HC Wainwright from $20.00 to $80.00 in a report issued on Monday, Marketbeat Ratings reports. The firm currently has a “buy” rating on the stock.

A number of other equities research analysts have also weighed in on ENLV. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. Zacks Research raised shares of Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Finally, Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 25th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $137.50.

View Our Latest Stock Analysis on ENLV

Enlivex Therapeutics Stock Performance

Shares of Enlivex Therapeutics stock opened at $2.09 on Monday. Enlivex Therapeutics has a 12-month low of $1.80 and a 12-month high of $31.50. The company has a market cap of $35.18 million, a P/E ratio of -0.25 and a beta of 1.52. The company’s fifty day simple moving average is $8.04 and its two-hundred day simple moving average is $12.38.

Hedge Funds Weigh In On Enlivex Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ENLV. Jane Street Group LLC lifted its position in Enlivex Therapeutics by 527.4% during the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after buying an additional 67,886 shares during the period. Susquehanna International Group LLP purchased a new stake in shares of Enlivex Therapeutics in the 3rd quarter worth about $57,000. Renaissance Technologies LLC grew its position in shares of Enlivex Therapeutics by 99.4% in the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock worth $221,000 after buying an additional 156,336 shares during the period. HRT Financial LP increased its stake in shares of Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after acquiring an additional 135,198 shares in the last quarter. Finally, XTX Topco Ltd increased its stake in shares of Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company’s stock worth $43,000 after acquiring an additional 19,132 shares in the last quarter. Institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

(Get Free Report)

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.

Recommended Stories